Quick Answer
Propanc Biopharma, Inc. reported Net Income of -$58.92 million for fiscal year 2025.
Propanc Biopharma, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$58.92M | -3136.6% |
| 2024 | -$1.82M | +31.6% |
| 2023 | -$2.66M | -0.1% |
| 2022 | -$2.66M | -31.2% |
| 2021 | -$2.03M | +57.3% |
| 2020 | -$4.74M | +17.7% |
| 2019 | -$5.76M | +18.2% |
| 2018 | -$7.04M | +10.5% |
| 2017 | -$7.87M | +16.4% |
| 2016 | -$9.41M | -175.7% |
| 2015 | -$3.41M | -311.4% |
| 2014 | -$829.6K | +42.5% |
| 2013 | -$1.44M | +87.4% |
| 2012 | -$11.43M | -431.3% |
| 2011 | -$2.15M | -155.4% |
| 2010 | -$842.5K | -89.8% |
| 2009 | -$443.8K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$3.09M | -618.6% | +36.1% |
| September 30, 2025 | -$4.84M | -1265.4% | +91.1% |
| March 31, 2025 | -$54.07M | -10165.3% | -12468.5% |
| December 31, 2024 | -$430.2K | +26.4% | -21.4% |
| September 30, 2024 | -$354.3K | -1.0% | +32.7% |
| March 31, 2024 | -$526.7K | +35.0% | +9.9% |
| December 31, 2023 | -$584.4K | -20.4% | -66.6% |
| September 30, 2023 | -$350.9K | +43.2% | +56.7% |
- Propanc Biopharma, Inc. showed a decrease of -3136.6% in Net Income compared to the prior fiscal year.
- Over the 2009–2025 period, Propanc Biopharma, Inc.’s net income has declined by 13175.5% (from -$443.8 thousand to -$58.92 million).
- The most recent figure is from Propanc Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: